Cargando…

CAR T cells targeting tumor endothelial marker CLEC14A inhibit tumor growth

Engineering T cells to express chimeric antigen receptors (CARs) specific for antigens on hematological cancers has yielded remarkable clinical responses, but with solid tumors, benefit has been more limited. This may reflect lack of suitable target antigens, immune evasion mechanisms in malignant c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhuang, Xiaodong, Maione, Federica, Robinson, Joseph, Bentley, Michael, Kaul, Baksho, Whitworth, Katharine, Jumbu, Neeraj, Jinks, Elizabeth, Bystrom, Jonas, Gabriele, Pietro, Garibaldi, Elisabetta, Delmastro, Elena, Nagy, Zsuzsanna, Gilham, David, Giraudo, Enrico, Bicknell, Roy, Lee, Steven P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Clinical Investigation 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7566713/ https://www.ncbi.nlm.nih.gov/pubmed/33004686 http://dx.doi.org/10.1172/jci.insight.138808

Ejemplares similares

An evaluation of the tumour endothelial marker CLEC14A as a therapeutic target in solid tumours
por: Robinson, Joseph, et al.
Publicado: (2020)

TEM8/ANTXR1-specific CAR T cells mediate toxicity in vivo
por: Petrovic, Kristina, et al.
Publicado: (2019)

Blocking CLEC14A-MMRN2 binding inhibits sprouting angiogenesis and tumour growth
por: PJ, Noy, et al.
Publicado: (2015)

CLEC2 and CLEC5A: Pathogenic Host Factors in Acute Viral Infections
por: Sung, Pei-Shan, et al.
Publicado: (2019)

Preclinical Assessment of CAR T-Cell Therapy Targeting the Tumor Antigen 5T4 in Ovarian Cancer
por: Owens, Gemma L., et al.
Publicado: (2018)

Inhibition of VEGF‐dependent angiogenesis and tumor angiogenesis by an optimized antibody targeting CLEC14a
por: Kim, Taek‐Keun, et al.
Publicado: (2018)

Platelets Promote Tumor Growth and Metastasis via Direct Interaction between Aggrus/Podoplanin and CLEC-2
por: Takagi, Satoshi, et al.
Publicado: (2013)

Overexpression of CLEC3A promotes tumor progression and poor prognosis in breast invasive ductal cancer
por: Ni, Jun, et al.
Publicado: (2018)

The development of CAR design for tumor CAR-T cell therapy
por: Xu, Dandan, et al.
Publicado: (2018)

Platelet CLEC‐2 and lung development
por: Suzuki‐Inoue, Katsue, et al.
Publicado: (2020)

Lymphatic blood filling in CLEC-2-deficient mouse models
por: Haining, Elizabeth J, et al.
Publicado: (2020)

Genetic association analysis of CLEC5A and CLEC7A gene single-nucleotide polymorphisms and Crohn’s disease
por: Elleisy, Nagi, et al.
Publicado: (2020)

Innovative CAR-T Cell Therapy for Solid Tumor; Current Duel between CAR-T Spear and Tumor Shield
por: Jo, Yuna, et al.
Publicado: (2020)

Editorial: Sentinel CLECs at Immunological Decision Nodes
por: Hoober, J. Kenneth, et al.
Publicado: (2020)

The Role of CLEC-2 and Its Ligands in Thromboinflammation
por: Meng, Danyang, et al.
Publicado: (2021)

CAR-Macrophages and CAR-T Cells Synergistically Kill Tumor Cells In Vitro
por: Liu, Maoxuan, et al.
Publicado: (2022)

CLEC1B Expression and PD-L1 Expression Predict Clinical Outcome in Hepatocellular Carcinoma with Tumor Hemorrhage()()
por: Hu, Kuan, et al.
Publicado: (2018)

EGFR Mutation-Harboring Lung Cancer Cells Produce CLEC11A with Endothelial Trophic and Tumor-Promoting Activities
por: Lin, Tzu-Yin, et al.
Publicado: (2022)

The uric acid crystal receptor Clec12A potentiates type I interferon responses
por: Li, Kai, et al.
Publicado: (2019)

The tumor vasculature an attractive CAR T cell target in solid tumors
por: Akbari, Parvin, et al.
Publicado: (2019)

High Expression of CLEC11A Predicts Favorable Prognosis in Acute Myeloid Leukemia
por: Yin, Chengliang, et al.
Publicado: (2021)

PDGF upregulates CLEC-2 to induce T regulatory cells
por: Agrawal, Sudhanshu, et al.
Publicado: (2015)

The podoplanin-CLEC-2 axis inhibits inflammation in sepsis
por: Rayes, Julie, et al.
Publicado: (2017)

Podoplanin and CLEC-2 levels in patients with COVID-19
por: Borba-Junior, Ivanio Teixeira, et al.
Publicado: (2023)

CAR-T Cells Hit the Tumor Microenvironment: Strategies to Overcome Tumor Escape
por: Rodriguez-Garcia, Alba, et al.
Publicado: (2020)

Extracellular vesicles from CLEC2-activated platelets enhance dengue virus-induced lethality via CLEC5A/TLR2
por: Sung, Pei-Shan, et al.
Publicado: (2019)

Lenalidomide normalizes tumor vessels in colorectal cancer improving chemotherapy activity
por: Leuci, V., et al.
Publicado: (2016)

Roadblocks to success for RNA CARs in solid tumors
por: Singh, Nathan, et al.
Publicado: (2015)

Editorial: CAR T-Cell Therapies in Hematologic Tumors
por: Coscia, Marta, et al.
Publicado: (2020)

CAR T Cell Therapy for Pediatric Brain Tumors
por: Patterson, John D., et al.
Publicado: (2020)

CAR T cells in solid tumors: challenges and opportunities
por: Marofi, Faroogh, et al.
Publicado: (2021)

CAR-NK Cells in the Treatment of Solid Tumors
por: Wrona, Ewa, et al.
Publicado: (2021)

CAR T Cell Locomotion in Solid Tumor Microenvironment
por: Nguyen, Duy T., et al.
Publicado: (2022)

CAR-T Therapies in Solid Tumors: Opportunities and Challenges
por: Guzman, Grace, et al.
Publicado: (2023)

CAR T-Cell Therapy in Children with Solid Tumors
por: Kulczycka, Marika, et al.
Publicado: (2023)

CAR-T-Derived Extracellular Vesicles: A Promising Development of CAR-T Anti-Tumor Therapy
por: Pagotto, Sara, et al.
Publicado: (2023)

Tumor Microenvironment Immunosuppression: A Roadblock to CAR T-Cell Advancement in Solid Tumors
por: Johnson, Abigail, et al.
Publicado: (2022)

Polymorphisms of CLEC16A Region and Autoimmune Thyroid Diseases
por: Muhali, Fatuma-Said, et al.
Publicado: (2014)

ASGR1 and Its Enigmatic Relative, CLEC10A
por: Hoober, J. Kenneth
Publicado: (2020)

CLEC4s as Potential Therapeutic Targets in Hepatocellular Carcinoma Microenvironment
por: Zhang, Yinjiang, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_0vnb312s1n9oiejqq94q957ium